亚洲日本欧美日韩高观看,香蕉免费一区二区三区,欧美激情a∨在线视频播放,国产国语在线播放视频

關鍵詞:
  首頁 > 美迪醫訊 > 法德兩公司聯合開發吸入皮質內固醇  

法德兩公司聯合開發吸入皮質內固醇

【?2005-07-09 發布?】 美迪醫訊
美迪網領先的醫療器械電子商務平臺

 
最新資料顯示:一種實驗性吸入皮質內固醇能夠顯著減少嚴重持續哮喘成年患者的口服皮質內固醇用量,同時能夠維持對哮喘癥狀的控制。2005年5月美國圣地亞哥舉行的美國胸科學會國際會上報道了這些資料。

Alvesco (ciclesonide)是一種吸入皮質內固醇,具有新型釋放和分布特性。吸入皮質內固醇能夠減輕肺部和氣道的炎癥,這些炎癥導致了疾病過程。

在一項為期12周的多國多中心141例嚴重持續哮喘患者的III期臨床試驗中,評估了口服皮質內固醇(OCS)用量減少以及環索奈德(CIC)替代治療的效果。結果顯示大約有30%使用環索奈德治療的患者能夠完全無需使用OCS。與安慰劑相比較,所有劑量的環索奈德都減少了OCS的基礎用量。相似的是,OCS給藥也能夠顯著改變環索奈德治療患者。最常報道的不良事件是鼻咽炎、頭痛和上呼吸道感染。

國家猶太醫療和研究中心教授Sally E. Wenzel說:“這些結果十分重要,因為口服皮質內固醇例如強的松能夠產生嚴重的系統不良事件,而這可以通過使用吸入皮質內固醇來減少。我們的研究結果發現:嚴重持續哮喘患者使用環索奈德治療能夠顯著降低口服皮質內固醇的使用。”

環索奈德是由法國Sanofi-aventis公司和德國Altana Pharma公司聯合研制開發的。 

Compound Reduces Oral Corticosteroid Use
 
New data show that an investigational inhaled corticosteroid can significantly reduce the use of oral corticosteroids in adults with severe, persistent asthma while maintaining asthma control. The data were presented at the International Conference of the American Thoracic Society in San Diego (CA, USA) in May 2005.

Alvesco (ciclesonide) is an inhaled corticosteroid with novel release and distribution properties. Inhaled corticosteroids work by reducing inflammation, the underlying disease process, in the lungs and airways.

The reduction of oral corticosteroid (OCS) use with the replacement of ciclesonide (CIC) was evaluated in a phase III, 12-week multinational, multicenter trial involving 141 patients with severe, persistent asthma. Results showed that about 30% of patients treated with ciclesonide were able to eliminate their OCS use entirely. All ciclesonide doses resulted in a significant percent change from baseline in OCS dose compared to placebo. Similarly, OCS dose was significantly changed from baseline in ciclesonide-treated patients. The most frequently reported adverse events were nasopharyngitis, headache, and upper respiratory tract infection.

“These findings are important because oral corticosteroids such as prednisone are known to cause systemic adverse events, which can be reduced by replacing them with inhaled corticosteroids,” said Sally E. Wenzel, M.D., professor at the National Jewish Medical and Research Center (Denver, Colorado). “Our study found a significant reduction in the need for oral corticosteroid use by patients with severe, persistent asthma who were treated with ciclesonide.”

Ciclesonide was jointly developed by the Sanofi-aventis Group (Paris, France) and Altana Pharma (Konstanz, Germany).

/**/
本文關鍵字: 皮質內固醇 
收藏本文到: Digg Live Bookmark Facebook 百度搜藏 新浪ViVi 365Key網摘 天極網摘 和訊網摘 POCO網摘 QQ書簽

  《美迪醫訊》歡迎您參與新聞投稿,業務咨詢: 美迪醫療網業務咨詢

我要評論:《法德兩公司聯合開發吸入皮質內固醇》
匿名發表 我的名字: Email: 驗證碼: 點擊可刷新
 
    

  更多關于 皮質內固醇  的新聞

合作支持:中華醫學會 | 中華醫院管理學會 | 國家食品藥品監督管理家用護理器械商城 | 國藥勵展展覽有限責任公 | 醫學裝備協會
刊登廣告 | 友情鏈接 | 廣告代理商加盟 | 關于美迪 | 法律聲明 | 隱私保護 | 網站地圖
把美迪網放進收藏夾  把美迪醫療網介紹給我的朋友  給美迪醫療網留言
美迪醫療網廣告業務聯系:021-51601230 產品咨詢業務聯系:021-51601230 傳真:021-56532303    美迪醫療網業務咨詢
互聯網藥品信息服務許可證:(滬)-經營性-2009-0003   中華人民共和國電信與信息服務業務經營許可證:(滬)B2-20090029 滬ICP備14001091號-8
 
公安備案號 31010602000199 醫療器械經營許可證: 滬靜藥監械經營許20210003號 第二類醫療器械經營備案憑證: 滬靜藥監械經營備20220042號
營業執照:統一社會信用代碼91310108676284138X互聯網藥品信息服務資格書:(滬)-非經營性-2023-0081
消防排煙風機 華創商務網
美迪醫療網廣告業務聯系:021-51601230  產品咨詢業務聯系:021-51601230 傳真:021-56532303   美迪醫療網產品咨詢 本QQ僅咨詢廣告和會員業務,不咨詢產品和藥品等業務美迪醫療網推廣業務咨詢